Provenance, Added Clinical Benefit and Therapeutic Area of 632 medicines that entered the French market between 2008 and 2018

This file contains a data set of 632 medicines that entered the French market between 2008 to 2018. 529 medicines are single drugs and 103 are combination medicines. For each drug we present data on provenance (inventor of the drug) and sources referencing our searches for origins of each medicine. We also present added clinical benefit data for all 632 medicines based on HAS and Prescrire matched grading scale as well as therapeutic area of each medicinal product in which the clinical benefit grading was sourced (highest clinical benefit grading attained by the product in the indication based on Prescrire grading). The file also contains data on the medicines approved by the FDA in the United States

Related Organizations

London School of Economics and Political Science
United Kingdom

Keywords

Combination drug origins, Added clinical benefit, French market, Therapeutic area, Provenance of medicines

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average